Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A16AB09

Elaprase(idursulfase)

Mucopolysaccharidosis II

Marketing Authorisation Holder: Takeda Pharmaceuticals International AG Ireland Branch

EMA Authorisation: 08/01/2007

INN: idursulfase

Indication

Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Elaprase — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.